Presentation ACC 2025 Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study Presenter: Isabelle Mahé March 29, 2025
News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
Presentation ACC 2022 Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial Presenter: Duk-Woo Park April 04, 2022
News Conference News ACC 2022 POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery Todd Neale April 02, 2022
News Conference News ACC 2021 ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 Todd Neale May 17, 2021
News Conference News ACC 2021 Low 1-Year Stroke Risk After Commercial Watchman Use Todd Neale May 15, 2021
News Conference News ACC 2020 Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair L.A. McKeown April 07, 2020
News Conference News ACC 2020 LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout Todd Neale April 06, 2020
News Conference News ACC 2020 Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients L.A. McKeown April 01, 2020
News Conference News ACC 2020 PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery Yael L. Maxwell March 31, 2020
News Conference News ACC 2020 A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI Todd Neale March 29, 2020
News Conference News ACC 2018 MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery Todd Neale March 11, 2018
News Conference News ACC 2017 Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients L.A. McKeown March 21, 2017
Presentation ACC 2017 EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Presenter: Jeff Weitz March 20, 2017
News Conference News ACC 2017 Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE L.A. McKeown March 18, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017